These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 10140661)

  • 1. Color as a trademark under the Lanham Act: confusion in the circuits and the need for uniformity.
    Carraway JC
    Law Contemp Probl; 1994; 57(4):243-79. PubMed ID: 10140661
    [No Abstract]   [Full Text] [Related]  

  • 2. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 3. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
    Paine CS
    Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 5. Antitrust issues in the settlement of pharmaceutical patent disputes, Part II.
    Leary TB
    J Health Law; 2001; 34(4):657-71. PubMed ID: 11833411
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Are reverse payments and pay-for-delay settlements business as usual or an anticompetitive practice?
    Shah S; Silva MA; Malloy MJ
    Nat Biotechnol; 2016 Jul; 34(7):716-9. PubMed ID: 27404880
    [No Abstract]   [Full Text] [Related]  

  • 7. Biotech industry considers foreign competition measure.
    Margolis RE
    Healthspan; 1990 Nov; 7(10):19-20. PubMed ID: 10107734
    [No Abstract]   [Full Text] [Related]  

  • 8. 3M ruling calls hospital, GPO contracts into question.
    Barlow RD
    Hosp Mater Manage; 1991 Sep; 16(9):1, 11. PubMed ID: 10114524
    [No Abstract]   [Full Text] [Related]  

  • 9. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
    Soehnge H
    Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
    [No Abstract]   [Full Text] [Related]  

  • 10. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 11. Hospital competition and antitrust: the Federal Trade Commission staff report.
    Miles JJ
    Health Law Vigil; 1987 Jul; 10(14):6-10. PubMed ID: 10282648
    [No Abstract]   [Full Text] [Related]  

  • 12. Generics battle brand names over mortality of drug patents.
    Betz R
    J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
    [No Abstract]   [Full Text] [Related]  

  • 13. General Electric may violate antitrust law with purchase of medical imaging business.
    Carter K
    Mod Healthc; 1986 Apr; 16(9):22. PubMed ID: 10276446
    [No Abstract]   [Full Text] [Related]  

  • 14. The health care industry and antitrust: a continuing exploration.
    Weissburg C; Waxman JM
    Rev Fed Am Hosp; 1983; 16(4):57, 60. PubMed ID: 10260804
    [No Abstract]   [Full Text] [Related]  

  • 15. Mergers and acquisitions in the health care industry.
    Duncheon MA; Goldman JS
    Health Law Vigil; 1986 Jul; 9(13):18-21. PubMed ID: 10277099
    [No Abstract]   [Full Text] [Related]  

  • 16. Antitrust in the health services industry: the first five years.
    Dolan AK
    Health Med Care Serv Rev; 1981-1982; 3(2-3):13, 15-24. PubMed ID: 10299261
    [No Abstract]   [Full Text] [Related]  

  • 17. The antitrust perspective on health industry competition.
    Miller FH
    J Health Hum Resour Adm; 1989; 12(1):128-48. PubMed ID: 10296433
    [No Abstract]   [Full Text] [Related]  

  • 18. The antitrust analysis of hospital mergers and the transformation of the hospital industry.
    Baker JB
    Law Contemp Probl; 1988; 51(2):93-164. PubMed ID: 10295967
    [No Abstract]   [Full Text] [Related]  

  • 19. The hard-selling supplier to the sick.
    Pillsbury AB
    Fortune; 1982 Jul; 106(2):56-61. PubMed ID: 10255942
    [No Abstract]   [Full Text] [Related]  

  • 20. Antitrust: medical device corporation liable for violating FTC order.
    Montgomery R
    J Law Med Ethics; 2002; 30(1):122-3. PubMed ID: 11905263
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.